Ligand Pharmaceuticals has patents filed for the manufacture and therapeutic use of certain compounds occupying several stated chemical structures, which are intended for use as selective androgen receptor modulators. The patent is filed under the following designations: US8519158 B2, US8865918, US9359285, US20070254875, US20140005186, US20150099720, and WO2005090282A1. The patents will expire on March 12, 2025. These patents effectively protect any future capitalization upon VK5211 in the market by Viking and Ligand through their licensing agreement. 
Tren- great medication, which gives excellent results on the path of "solo" to increase muscle mass without the need to be combined with other medications. However, it is a very powerful steroid, and therefore do not exceed the recommended dosage of certain: for acetate - is 50mg per day for enthatate: 300-350mg per week. To test the tolerance of Tren is better to start with a minimum dosage. If the entire rate is not more than six weeks, the need for additional formulations appears; when 6 to 8 weeks, with the need to enter the second week Gonadotropin (500 / 1000ME every 7 days) and stop taking it two weeks after administration cycle. Next, we have to be post-cycle therapy: start 14 days after the last injection or after 3days (if used Tren Acetate). To restore testosterone production take testosterone boosters (4 weeks after the course).